Novartis, Cepheid Hope to Improve Bcr-Abl Transcript Monitoring in Gleevec-Treated CML Patients

Novartis is hoping to reduce variability in Bcr-Abl transcript monitoring by developing and commercializing a test that reports results in line with a standard called the International Scale.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.